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Background: Tobacco cessation medication adherence is one of the few factors shown to improve smoking cessation
rates among methadone-maintained smokers, but interventions to improve adherence to smoking cessation medications
have not yet been tested among methadone treatment patients. Methadone clinic-based, directly observed therapy
(DOT) programs for HIV and tuberculosis improve adherence and clinical outcomes, but have not been evaluated
for smoking cessation. We describe a randomized controlled trial to evaluate whether a methadone clinic-based,
directly observed varenicline therapy program increases adherence and tobacco abstinence among opioid-dependent
drug users receiving methadone treatment.
Methods/Design: We plan to enroll 100 methadone-maintained smokers and randomize them to directly observed
varenicline dispensed with daily methadone doses or treatment as usual (self-administered varenicline) for 12 weeks.
Our outcome measures are: 1) pill count adherence and 2) carbon monoxide-verified tobacco abstinence. We will
assess differences in adherence and abstinence between the two treatment arms using repeated measures models.
Discussion: This trial will allow for rigorous evaluation of the efficacy of methadone clinic-based, directly observed
varenicline for improving adherence and smoking cessation outcomes. This detailed description of trial methodology
can serve as a template for the development of future DOT programs and can guide protocols for studies among
opioid-dependent smokers receiving methadone treatment.
Trial Registration: clinicaltrials.gov NCT01378858
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disordersBackground
Methadone maintenance treatment patients have a dis-
proportionately high prevalence of tobacco use and suf-
fer high rates of tobacco-related disease and mortality
[1-6]. Cessation approaches evaluated to date among
opioid-dependent smokers, including nicotine replace-
ment therapy, bupropion, or varenicline in combination
with behavioral therapy, have not been effective over
control conditions [7-11]. Varenicline’s demonstrated effi-
cacy may not be generalizable to methadone-maintained* Correspondence: snahvi@montefiore.org
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unless otherwise stated.smokers because of poor adherence, which is highly
prevalent among drug users [11-15]. Though adherence
to smoking cessation treatment is a critical determinant
of successful cessation [16-23] and adherence is one of the
few factors shown to increase cessation among methadone-
maintained smokers [12,24,25], interventions to improve
adherence to smoking cessation pharmacotherapy have not
yet been tested in this group.
Administration of directly observed therapy (DOT) for
tuberculosis (TB) and HIV regimens at opioid agonist treat-
ment programs has been shown to improve adherence and
clinical outcomes among methadone maintenance patients
[26-30]. Methadone maintenance programs provide an
ideal setting for DOT administration. Regulatory require-
ments mandate that patients attend methadone programstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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herence, and providing a platform for treatment of other
diseases. Because of the limited treatment course and low
pill burden of smoking cessation treatment, it may be even
more feasible to implement DOT for smoking cessation
treatment than for TB or HIV treatment. To our know-
ledge, no studies to date have evaluated DOT for smoking
cessation.
We thus designed a randomized trial of modified, di-
rectly observed versus self-administered varenicline therapy
in methadone clinics to evaluate the efficacy of modified
DOT (mDOT) for improving varenicline adherence and
smoking cessation among methadone-maintained smokers,
and to test whether drug use and psychiatric symptoms
moderate the effects of mDOT on adherence.
Methods/Design
This is a randomized pilot trial of modified directly ob-
served versus self-administered varenicline therapy among
100 methadone-maintained smokers. We will evaluate the
efficacy of mDOT varenicline for promoting smoking ces-
sation and medication adherence with research visits at
baseline and at 1, 2, 3, 6, 9, 12, and 24 weeks. We will also
evaluate the moderating effects of illicit drug use and
psychiatric symptoms on mDOTadherence effects.
Study setting
Participants will be recruited from the Einstein Division
of Substance Abuse (DoSA) methadone clinics, which
offer integrated substance abuse and medical treatment
to 3200 patients in three clinical sites in the Bronx, New
York. Established in 1968, DoSA is a clinical, research,
and educational division of the Einstein Department of
Psychiatry. Each clinic offers comprehensive medical ser-
vices, integrating general and HIV-related medical and
gynecologic services with co-located substance abuse
treatment.
Participants
Our goal is to enroll subjects representative of methadone-
maintained smokers, while considering varenicline precau-
tions. Eligible persons are: 18 years or older; smoking 5
or more cigarettes per day; interested in quitting smok-
ing with a plan to quit in ≤ 6 months (ladder of change
score 6–8); enrolled in methadone treatment for at
least 3 months, receiving methadone in the clinic 3, 4,
5, or 6 times per week, without three or more clinic ab-
sences in the prior 2 weeks; English-speaking; able to
provide informed consent; not pregnant, breastfeeding,
or trying to conceive; and have not taken varenicline in
the past 30 days. Unstable liver, cardiac, pulmonary,
renal, or infectious diseases are exclusionary. Psychi-
atric exclusion criteria include current major depressive
or manic episode, current psychotic disorder, past-yearsuicide attempt or psychiatric hospitalization, or current
suicidal ideation with plan or intent.
Subjects will be recruited by research assistants in
methadone clinic waiting areas, as well as by word-of-
mouth, posted fliers, and clinic counseling and medical
staff referral. All subjects will sign written informed con-
sent. We will conduct a brief screening interview, then
abstract laboratory and treatment data from clinic charts
to further assess eligibility. Eligibility will be confirmed only
after the study physician completes a clinical and struc-
tured psychiatric interview using the Mini-International
Neuropsychiatric Interview 6.0.0 (M.I.N.I.) and Columbia
Suicide Severity Rating Scale, and conducts a physical
examination and urine pregnancy test (if applicable).
Interviews will be completed in private offices in the
methadone clinics.
Interventions
Subjects will receive varenicline for 12 weeks, using stand-
ard dosing: 0.5 mg once daily for 3 days, then 0.5 mg twice
daily for 4 days, followed by 1 mg twice daily for 11 weeks.
Subjects will be randomly assigned to receive varenicline
via: 1) treatment as usual (TAU) or 2) modified directly
observed therapy (mDOT). Most subjects will have public
insurance that should cover the cost of varenicline; for
those who do not, varenicline will be purchased from a
local pharmacy using research funds.
DOT Intervention
Subjects in the mDOT arm will receive: 1) directly ob-
served varenicline doses at the same time as they receive
a methadone dose at their methadone program, between
3 and 6 times per week; and 2) take-home doses pack-
aged in individual pill boxes for self-administration on
days off and evenings (Figure 1). In addition, methadone
clinic nurses will assess side effects using a standard
script and will refer subjects to on-site medical providers
for treatment if side effects are reported.
We describe the intervention as ‘modified directly ob-
served therapy’ because varenicline ingestion will be ob-
served at the methadone window 3–6 days per week
based on the subject’s methadone clinic schedule. Fur-
thermore, varenicline is a twice-daily medication, and
only one of two daily varenicline doses can be observed.
For example, if a subject receives methadone at his/her
program Monday through Saturday and a take-home
dose of methadone on Sunday, s/he would receive ob-
served varenicline at the same time s/he receives metha-
done Monday through Saturday (for a total of six
observed doses), and would get pill boxes for evening
and Sunday varenicline doses (eight unobserved doses
weekly). Subjects will be instructed to return the pill
boxes for unobserved doses at their next clinic visit,
whether or not they have taken the pills.
A. Methadone clinic visits three days per week 




Varenicline 1 mg 
Take in AM
MONDAY
Varenicline 1 mg 
Take in AM
TUESDAY
Varenicline 1 mg 
Take in AM
WEDNESDAY
Varenicline 1 mg 
Take in AM
THURSDAY
Varenicline 1 mg 
Take in AM
FRIDAY
Varenicline 1 mg 
Take in AM
SATURDAY
Varenicline 1 mg 
Take in AM
SUNDAY
Varenicline 1 mg 
Take in PM
MONDAY
Varenicline 1 mg 
Take in PM
TUESDAY
Varenicline 1 mg 
Take in PM
WEDNESDAY
Varenicline 1 mg 
Take in PM
THURSDAY
Varenicline 1 mg 
Take in PM
FRIDAY
Varenicline 1 mg 
Take in PM
SATURDAY
Varenicline 1 mg 
Take in PM
SUNDAY
Varenicline 1 mg 
Take in AM
MONDAY
Varenicline 1 mg 
Take in AM
TUESDAY
Varenicline 1 mg 
Take in AM
WEDNESDAY
Varenicline 1 mg 
Take in AM
THURSDAY
Varenicline 1 mg 
Take in AM
FRIDAY
Varenicline 1 mg 
Take in AM
SATURDAY
Varenicline 1 mg 
Take in AM
SUNDAY
Varenicline 1 mg 
Take in PM
MONDAY
Varenicline 1 mg 
Take in PM
TUESDAY
Varenicline 1 mg 
Take in PM
WEDNESDAY
Varenicline 1 mg 
Take in PM
THURSDAY
Varenicline 1 mg 
Take in PM
FRIDAY
Varenicline 1 mg 
Take in PM
SATURDAY
Varenicline 1 mg 
Take in PM
Figure 1 Example mDOT varenicline pill trays. A. Methadone clinic visits 3 days per week. B. Methadone clinic visits 6 days per week. This figure
illustrates mDOT varenicline pill box labels indicating observed and take-home varenicline doses, according to subjects’ methadone clinic schedule.
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be prepared by research assistants, indicating varenicline
dosing and dates of administration, and color-coded la-
bels will indicate whether the dose is directly observed
or self-administered (for days off and evenings). Each
tray will hold seven removable pill boxes, with compart-
ments for morning and evening varenicline doses. The
study physician will call in varenicline prescriptions to a
single, designated, community pharmacy that delivers
medications to the DoSA central pharmacy. Empty, la-
beled trays also will be delivered to the central DoSA
pharmacist, who will fill pill boxes with varenicline for
each subject. Filled trays will be delivered from the cen-
tral pharmacy to the methadone clinics every 2 weeks,
along with scheduled methadone deliveries.
TAU Control condition
Subjects in the TAU arm will pick up prescribed vareni-
cline from a local pharmacy of their choosing and self-
administer all varenicline doses (once daily for 3 days,
then twice daily).
Counseling and medication education
All subjects in both groups will receive a single session
of brief, physician, smoking cessation counseling based
on the Public Health Service 5As framework (ask, assess,
advise, assist, arrange follow-up) [31]. Brief advice has
been shown to increase the likelihood of successful smok-
ing cessation [31], is associated with outcomes comparable
to tailored motivational counseling among methadone-maintained smokers [8], and is easily implemented in
complex clinical settings. Subjects also will receive a bro-
chure promoting medication adherence, as well as verbal
and written instructions on varenicline administration and
management of anticipated side effects. If subjects report
persistent or severe treatment-emergent symptoms over
the intervention period, they will meet with the study
physician for assessment and brief counseling on symp-
tom management.
Randomization
Subjects will be randomized a 1:1 ratio in variable size
blocks of 2–8 via central, computer-generated randomization.
Randomization will be stratified by clinical site and
HIV status. We will randomize in blocks to ensure
comparison groups of approximately equal size. To en-
sure concealment of allocation, a centrally-located data
manager will generate the allocation sequence and store
the sequence in a password-protected file. After the
study physician confirms a subject’s eligibility, she will
call the data manager, who will assign the subject to a
treatment group. Since the intervention is not blinded,
we will vary block size to prevent anticipation of treat-
ment arm assignment.
Visit schedule and measures
Research visits will be scheduled at baseline and at weeks
1, 2, 3, 6, 9, 12, and 24 (Table 1). We will collect survey
data using Audio Computer-Assisted Self-Interview
(ACASI), which has been shown to improve reporting of
Table 1 Timing of study measures
Baseline/Start Rx End of treatment
Week 1 2 3 6 9 12 24
Study measures
Sociodemographic characteristics X
Tobacco use behavior, FTNDa X X X X X X
Smoking endpointsb X X X X X
Medication adherence X X X X X X
Mini-International Neuropsych. Interview X X X X X X
Modified scale for suicidal ideation X X X X X
Brief symptom Inventory X X X X X X
Medication adverse events X X X X X X
Alcohol and other drug use X X X X X X
Urine toxicology tests X X X X
Medication adverse events X X X X X X
Subject reimbursement
$ Amountc $15 $10 $10 $15 $15 $15 $15 $15
aFagerström Test for Nicotine Dependence.
bCarbon monoxide-verified abstinence, number of cigarettes smoked per day, Fagerström Test for Nicotine Dependence score, quit attempts lasting ≥ 24 hours.
cTo ensure pill count completion, TAU subjects will be given partial reimbursement ($5-$10 dollars per visit) for research assessments and $5 for completion of pill
counts at each follow-up visit during the intervention period.
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$110 for completing all research assessments. Retention
will be enhanced by flagging subjects for research visits at
the methadone clinic reception desk, tracking contact in-
formation of subjects and their close contacts at each study
visit, reimbursement for completion of assessments, and
on-site data collection at subjects’ clinics.
Adherence measures
Our primary outcome is adherence (as a continuous meas-
ure) by pill count. Pill counts are an objective measure that
have been shown to correlate with electronic monitors
[32]. The amount of medication taken during the 12-week
treatment course will be expressed as a percentage of the
target dose. These are established measures used in other
DOT trials in our setting [29,33]. Self-report is the most
practical adherence measure for clinical use, and it has
been shown to correlate with clinically relevant outcomes
in several studies [34-37]. Though self-report is subject to
recall and reporting bias and may overestimate adherence
[32,36,38,39], we will use self-report as a second measure
of adherence because it is easy to administer and is
generalizable. Because electronic monitors (using medica-
tion event monitoring systems [MEMs]) cannot be used in
the mDOTarm, we have chosen not to use MEMs.
Tobacco use measures
Our primary tobacco use outcome is biochemically vali-
dated 7-day point prevalence abstinence at each follow-up
visit, with abstinence defined as including both self-reported smoking abstinence and carbon monoxide
(CO) < 8 p.p.m. (Micro Smokerlyzer®, Bedfont Scientific)
[40]. Self-reported tobacco abstinence will be measured
at all visits by asking participants, “Have you smoked at
least part of a cigarette in the past 7 days, even a puff?”
Our secondary tobacco outcome measures include: 1)
number of cigarettes smoked per day; 2) Fagerström
Test for Nicotine Dependence score; 3) quit attempts
lasting ≥ 24 hours; and 4) durability, measured by CO-
verified tobacco abstinence at week 24.
Potential moderating variables: psychologic symptoms
We will assess incident psychologic symptoms at weeks 3,
6, 9, and 12 using: 1) M.I.N.I. [41], which is a short, struc-
tured, diagnostic interview for DSM-IV Axis I disorders;
2) the Columbia Suicide Severity Rating Scale, a struc-
tured interview that assesses suicidal ideation, plans,
intent, and behavior [42]; and 3) the Brief Symptom
Inventory (BSI [43]), a measure of general psychological
symptom status that can be monitored over time.
Potential moderating variables: Alcohol and drug use
We will assess alcohol and drug use at baseline and at
weeks 3, 6, 9, and 12 via: 1) the Addiction Severity Index,
Lite version [44]; 2) the Alcohol Use Disorders Identifica-
tion Test [45]; and 3) urine toxicology tests.
Medication adverse effects
Adverse events will be evaluated at each follow-up visit
during the intervention period, using both a structured
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toms that have been reported among varenicline subjects
in published clinical trials, and an open-ended review of
treatment-emergent symptoms, defined as symptoms that
emerged or increased in intensity following the start of
study medication.
Major hypotheses and analytic plans
We will review and summarize data using descriptive
summaries and graphical analyses to ensure recorded
values are within appropriate ranges and to check for
outliers and abnormal values. Interim analyses will not
guide recruitment decisions.
Varenicline adherence
We hypothesize that adherence in the mDOT arm will
be higher than in the TAU arm throughout the interven-
tion period. We will apply a mixed effects linear model
to test the significance of the mDOT effect on the re-
peatedly measured pill count adherence outcome at
weeks 1, 2, 3, 6, 9, and 12. This model accounts for
within-subject longitudinal outcome correlation by tak-
ing the subject-level intercept as random, and it is ro-
bust in the context of missing data. The model will also
include variables not equally distributed between the
study arms at baseline, as well as psychiatric symptoms
and substance abuse. All analyses will use an intent-to-
treat approach.
Tobacco use
We hypothesize subjects in the mDOT arm will have
greater CO-verified, 7-day point prevalence abstinence
throughout the intervention period; reductions in ciga-
rettes/day and Fagerström Test for Nicotine Dependence
scores; and ≥ 24-hour quit attempts compared to sub-
jects receiving self-administered varenicline. We will
compare the proportion of participants who achieve
CO-verified tobacco abstinence at all follow-up time-
points in the two study arms using mixed-effects
models. In addition, we will compare secondary tobacco
use outcomes between study arms using chi-square or
Wilcoxon rank sum tests, and explore differences in
CO-verified abstinence at 24 weeks using Fisher exact
tests. All analyses will use an intent-to-treat approach. In
addition, we will apply mixed effects models to test the
significance of varenicline adherence on smoking cessa-
tion across the post-baseline assessment time points.
Moderating effects of drug use and psychiatric symptoms
We hypothesize that ongoing drug use and psychiatric
symptoms will negatively moderate adherence effects.
The dependent variable will be varenicline adherence.
Potential moderating variables include cocaine, heroin,
benzodiazepine, or marijuana use (defined as a binaryvariable based on either self-reported use or positive
urine toxicology result); hazardous alcohol use (defined
as AUDIT score ≥ 8 for men and ≥ 4 for women); inci-
dent major depressive, manic, or psychotic episodes;
suicidal ideation with plan or intent; and symptoms of
psychologic distress (BSI Global Severity Index T
score ≥ 63). We will test moderators using a treatment
group x moderating variable interaction term, and set an
alpha significance level of 0.15 for interaction analyses.
Sample size and power considerations
Among methadone-maintained smokers receiving a nico-
tine patch in a clinical trial, overall adherence over 90 days
was 44.1 percent [12]. Assuming a 13-percent difference
in adherence between the DOT and TAU groups as seen
in weeks 2–12 of a methadone clinic-based antiretroviral
DOT trial [30], the hypothesized adherence effect would
be 57 percent in the mDOT arm and 44 percent in the
TAU arm. We estimate sample sizes N per group re-
quired to detect this effect at a two-sided α = 0.05 as N
per group = 11, 14, and 17 for intraclass correlation
(ICC) = 0.1, 0.2, and 0.3, respectively.
Given that the efficacy of NRT and bupropion in
methadone maintenance patients has been half of that
observed in clinical trials of these medications in the
general population [7,8,15], we estimate that abstinence
rates at 12 weeks in the TAU varenicline arm would be
22 percent. We estimate that increased adherence would
double the odds of cessation [13,17,18,46], and thus the
abstinence rates at 12 weeks in the DOT arm would be
44 percent. We estimate sample sizes required to detect
the hypothesized intervention effect (22% and 44% on
a binary scale) at a two-sided alpha = 0.05 as N per
group = 29, 33, 38 for within-subject ICC = 0.1, 0.2,
and 0.3, respectively. Estimating an approximately 25
percent attrition rate at 12 weeks, we plan to recruit
100 participants.
Dissemination policy
We will disseminate study findings at national scientific
meetings and in published manuscripts. On request, we
will also share study protocols and de-identified study
data with investigators for research purposes. No study
participants will be individually identified in any pub-
lished or shared data.
Study design considerations
Optimizing pill count adherence measurement
For mDOT arm subjects, varenicline dosing will be eval-
uated by directly counting unconsumed varenicline pills
remaining behind the methadone window, as well as
those returned to nurses in pill boxes. Unobserved doses
in unreturned pill boxes will be counted as nonadher-
ence. Each day, nurses also will complete a pre-printed
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refused, or if the subject missed clinic.
Since a 4-week supply of 1 mg varenicline tablets can
be dispensed in bottles (containing 56 tablets) or in four
weekly blister packs (each containing 14 tablets), TAU
group subjects will be asked to bring in the full month’s
supply of medication to each study visit for pill counting.
For TAU arm subjects, research assistants will count
pills remaining in varenicline bottles or blister packs at
weeks 1, 2, 3, 6, 9, and 12. Given that TAU subjects ob-
tain a 4-week supply of medication at a time from com-
munity pharmacies, and that pill-count adherence would
be challenging to interpret if no pills were remaining, we
designed the research visit schedule to assess pill count
adherence separately from the every-4-week medication
dispensing intervals. To ensure pill count completion,
TAU group subjects will be given partial reimbursement
($5-$10 dollars per visit) for completion of research as-
sessments and $5 for completion of pill counts at each
follow-up visit during the intervention period.
Protection of study subjects
Confidentiality and research protections
The trial was approved by the Einstein Committee on
Clinical Investigations. All subjects will complete an in-
formed consent process and provide written consent.
We also obtained a Certificate of Confidentiality from
the National Institute on Drug Abuse to protect against
disclosure of research information in federal, state, or local
civil, criminal, or administrative proceedings. We estab-
lished a Data Safety and Monitoring Committee (DSMC),
composed of two senior clinical investigators with expertise
in clinical trials. We will report trial progress to the DSMC
quarterly, along with incident psychiatric illness, serious or
unanticipated adverse events, pregnancies, and protocol
deviations, and we will meet formally twice a year.
Addressing varenicline risk potential
Case reports of behavior change, agitation, depression,
and suicidality among patients taking varenicline led to
an FDA boxed warning in 2009 [47]. Despite a growing
body of research demonstrating the safety of varenicline
among patients with mental illness and substance use
disorders [48-56], we will take multiple precautions to
address varenicline’s psychiatric risk potential.
Prior to enrollment, information regarding potential
psychiatric risks will be discussed with subjects during
the informed consent process. During screening, a phys-
ician will assess potential subjects for current psychiatric
illness or suicidal ideation using structured instruments.
Individuals with psychiatric symptoms not receiving psy-
chiatric care will be referred to a mental health center.
Subjects will be assessed for incident psychiatric symp-
toms throughout the intervention period. At brief visits(weeks 1 and 2), and weeks 3, 6, 9 and 12, the inter-
viewer will ask open-ended questions about symptoms
that have emerged or increased in intensity since the
prior visit. At week 3, 6, 9, and 12 follow-up visits, psy-
chiatric symptoms will be assessed via structured instru-
ments. Prior to concluding the research visit, the research
assistant will review flags programmed into the computer-
ized survey record for symptoms consistent with incident
major depressive or manic episode, psychotic disorder, or
suicidal ideation and will refer subjects to outpatient or
emergency treatment according to detailed study protocols.
If subjects meet criteria for current major depressive
or manic episode, psychotic disorder, or suicidal ideation
with plan or intent, varenicline will be discontinued. To
facilitate medication discontinuation among TAU group
subjects who fill varenicline prescriptions at community
pharmacies of their choosing, prescriptions will not be
given directly to study subjects; rather, the study physician
will call in all prescriptions and track the pharmacies used.
If DOT group subjects meet criteria for medication dis-
continuation, the study physician will notify the study
pharmacy and the methadone clinic nurses.
Discussion
This study represents the first randomized controlled
trial of directly observed smoking cessation treatment in
a methadone program. Our trial draws on prior work
demonstrating the feasibility and efficacy of directly ob-
served HIV and TB treatment [26-30] and extends this
research to evaluate smoking cessation medication. Out-
comes from this trial will contribute to knowledge about
whether varenicline DOT is efficacious at promoting ad-
herence and smoking cessation among methadone main-
tenance patients.
Multiple studies suggest that smoking cessation medica-
tion adherence is an important determinant of cessation
success [16-21], including among methadone-maintained
smokers [12,24,25]. In a retrospective cohort study in
which methadone maintenance patients were prescribed
varenicline during routine clinical care, varenicline treat-
ment duration was significantly associated with smoking
cessation [25]. In two large smoking cessation trials among
methadone maintenance patients, adherence to nicotine
patch treatment was also shown to be associated with im-
proved smoking cessation outcomes [12,24]. Methadone-
maintained smokers had fewer cigarettes per day and a
7.1x increased odds of abstinence on days in which they
used patches compared to days they did not [12]. This
supports the importance of developing and evaluating in-
terventions to promote varenicline adherence.
Our trial has several strengths. Participants will be
randomly assigned to receive DOT or self-administered
varenicline. We will use objective measures of both ad-
herence and smoking cessation. The core components of
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over existing clinic operating budgets. We will not pro-
vide salary support for nurses, and medications will be
paid for by subjects’ existing insurance plans. We will
supply pill boxes used for DOT, and we will pay the
DoSA central pharmacist a stipend for filling the pill
boxes.
This study also has limitations. Reasons for medica-
tion nonadherence are multifaceted. While a DOT strat-
egy cannot address many potential adherence barriers,
DOT interventions have demonstrated efficacy for im-
proving adherence and clinical outcomes in TB and
HIV. Generalizability to opioid-dependent persons out-
side of drug treatment may be limited. Nonetheless,
over 200,000 people are enrolled in methadone pro-
grams in the US, over 80 percent of methadone main-
tenance patients smoke, and a significant number of
methadone programs offer linked primary care services,
including TB and HIV care. Furthermore, if proven ef-
fective, a DOT model could be used in other inpatient
and outpatient substance abuse treatment settings. Fi-
nally, our modest sample size may not allow us to de-
finitively evaluate moderating variables or to compare
tobacco abstinence rates between the mDOT and TAU
groups for smaller effect sizes. When we designed this
study, there were no published studies on varenicline
effects among methadone-maintained smokers. We have
since completed a placebo-controlled trial of varenicline
without DOT, in which 10.5 percent of varenicline-treated
subjects were abstinent [57]. In another trial of vareni-
cline, only 4 percent of methadone-maintained smokers
achieved abstinence at the end of treatment [11].
Despite these potential limitations, we feel that our de-
sign will allow for a controlled evaluation of intervention
effects, and our sample size will be adequate to assess
adherence in both arms and to inform effect size estima-
tion for future studies of smoking cessation interven-
tions among methadone maintenance patients. Even if the
cessation effect of this intervention is small, the potential
health impact may be large, given the high prevalence of
tobacco use and tobacco-related illness in substance abuse
treatment patients.
This study has the potential to improve smoking ces-
sation treatment outcomes and to inform the dissemin-
ation of smoking cessation services among substance
abuse treatment patients. This, in turn, may reduce the
disproportionate prevalence and associated disease bur-
den of tobacco use in this difficult-to-treat group.
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